Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.

Although differences in individual adverse event categories did not reach statistical significance, higher frequencies of CRS and ICANS were consistently observed in the PLR-high group, including any grade CRS (100% vs. 75%; p = 0.47; Figure 3B ), grade 3–4 CRS (42.9% vs. 12.5%; p = 0.28; Figure 3C ), and any grade ICANS (57.1% vs. 12.5%; p = 0.12; Figure 3D ).

also in 111,027 other papers